{"id":"NCT03517449","sponsor":"Eisai Inc.","briefTitle":"Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])","officialTitle":"A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-11","primaryCompletion":"2020-10-26","completion":"2025-02-26","firstPosted":"2018-05-07","resultsPosted":"2021-11-17","lastUpdate":"2025-06-15"},"enrollment":827,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Endometrial Neoplasms"],"interventions":[{"type":"DRUG","name":"Pembrolizumab","otherNames":["KEYTRUDA®","MK-3475"]},{"type":"DRUG","name":"Lenvatinib","otherNames":["LENVIMA®"]},{"type":"DRUG","name":"Paclitaxel","otherNames":["TAXOL®"]},{"type":"DRUG","name":"Doxorubicin","otherNames":["ADRIAMYCIN®"]}],"arms":[{"label":"Lenvatinib 20 mg + Pembrolizumab 200 mg","type":"EXPERIMENTAL"},{"label":"Treatment of Physician's Choice","type":"ACTIVE_COMPARATOR"}],"summary":"This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice. The primary study hypothesis is that pembrolizumab in combination with lenvatinib prolongs progression free survival (PFS) and overall survival (OS) when compared to treatment of physician's choice.","primaryOutcome":{"measure":"Progression-free Survival (PFS)","timeFrame":"From the date of randomization to the date of the first documentation of disease progression or death, whichever occurred first or up to data cutoff date 26 October 2020 (up to approximately 2 years 5 months)","effectByArm":[{"arm":"Lenvatinib 20 mg + Pembrolizumab 200 mg","deltaMin":7.2,"sd":null},{"arm":"Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel","deltaMin":3.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":169,"countries":["United States","Argentina","Australia","Brazil","Canada","Colombia","France","Germany","Ireland","Israel","Italy","Japan","Mexico","New Zealand","Poland","Russia","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["38302725","37523661","37086595","37058687","35045221"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":214,"n":406},"commonTop":["Nausea","Diarrhoea","Anaemia","Hypertension","Decreased appetite"]}}